Sullivan helps drugmaker sell to Merck
Sullivan & Cromwell LLP advised hepatitis C drug developer Idenix Pharmaceuticals Inc. in its $3.85 billion sale to Merck & Co., a deal announced Monday.
Merck will pay $24.50 per share in cash under the terms of the deal. The company is employing a two-step tender offer and is acquiring Idenix through a subsidiary. Boards of directors at both com...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In